|
|
||||||||||||||||||
Article Navigation
|
The Risk of recurrence in prostate cancerby: Fritz Frei Prostate cancer disease Prostate cancer - the most common form of cancer in men is Prostate cancer, the second leading cause of cancer death. The Main risk factors include age (incidence increases in men over the age of 65 years). It is more prevalent in the western world and about 10% of cases can be linked to family history. The recurrance Rate of the prostate cancer is high. Mostly, the Prostate cancer is a continuum; progressing through localized, locally advanced, advanced and hormone-refractory stages In general it is a slow growing cancer. He is primarily under hormonal control i.e. testosterone. The choice of treatments which include watchful waiting, surgery (prostatectomy), radiotherapy, hormonal therapy and chemotherapy are dependent on the stage of disease. 1. Most important, that If detected early, using PSA determination, DRE examination and biopsies, and treated appropriately, survival rates are excellent. 2. The most critical focus for the treatment of prostate cancer is to treat those cancers where it is necessary. 3. The Decisions about the best management of prostate cancer can be very complex and depend upon the: - Pathology of the cancer (unlike other cancers, prostate cancer often progresses very slowly) - The impact that treatment can have on quality of life, including sexual activity - Stage of the disease (non-metastatic (localized or locally advanced), metastatic or hormone refractory) - Age and general health of the patients at diagnosis - Patient’s preference for treatment - PSA at diagnosis 4. The treatment options for prostate cancer are: - Deferred treatment often called ‘watchful waiting’ or 'active surveillance' - Surgery – Radical Prostatectomy - Radiotherapy – External Beam and/or Brachytherapy -Hormonal (endocrine) therapy – Androgen Ablation e.g. anti-androgens, medical castration (LHRHa) or surgical castration - Chemotherapy - Palliative Therapy e.g. chemotherapy - Investigational Therapies Prostate Cancer Recurrence Rates *** Prostate cancer is now detected at earlier stages due to heightened awareness and improved screening techniques. Despite definitive therapy, cancer cells may remain and can go undetected for years until they develop into metastatic disease. The risk of recurrence is high, suggesting there is a need to improve treatment approaches. Therefore, it is important to predict pathological stage and risk of disease recurrence early, so that appropriate treatment and/or monitoring can be initiated. The result's of all new treatments will bring us in the future the chance of a lower prostate recurrance. **You can inform you about the recurrence Rates on: http://www.prostateline.com/prostatelinehcp/9898_15850_8_0_0.aspx This gives you an overview with a study case – and the results. Health-Service-Online Admin Fritz http://www.cancer-info.info Latest Cancer News:Cancer drug dramatically shrinks prostate tumors, study finds (Los Angeles Times) The survival rate more than doubles among most of the men with aggressive cancers. A second, wider test shows similar results. 'Spectacularly effective,' a researcher says. An experimental cancer drug shrank prostate tumors dramatically and more than doubled survival in 70% to 80% of patients with aggressive cancers, British researchers reported Tuesday. Symphony director's kidney cancer removed (CNN.com) BOSTON, Massachusetts (AP) -- A growth on a kidney removed from conductor James Levine was malignant, but doctors say the cancer was caught early and no further treatment is needed, the Boston Symphony Orchestra said in a statement Tuesday. More Cancer Lymph Nodes Analyzed at Specialty Centers (HealthDay via Yahoo! News) TUESDAY, July 22 (HealthDay News) -- Patients with stomach or pancreatic cancer may have more lymph nodes examined for the spread of cancer if they're treated at designated comprehensive cancer centers or at hospitals that do a high number of cancer surgeries, says a U.S. study. Advance vs. prostate cancer (Denver Post) An experimental cancer drug shrank prostate tumors dramatically and more than doubled survival in 70 percent to 80 percent of patients with aggressive cancers, British researchers reported Tuesday. Drug combats untreatable prostate cancer (UPI) LONDON, July 22 (UPI) -- The Phase 1 clinical trial of the drug abiraterone revealed significant tumor shrinkage in men with advanced prostate cancer, researchers in Britain said. Cancer society bus coming to Naperville, Schaumburg (Daily Herald) The American Cancer Society Cancer Action Network is on tour, encouraging people to get involved in the political end of the fight against a disease that ranks among the top killers in the country. Prostate cancer drug hailed as breakthrough (The New Zealand Herald) A new prostate cancer drug showing stunning results in Britain could successfully treat hundreds of New Zealand men. Breast cancer survivor to speak at conference (The Press-Enterprise) RIVERSIDE - Nikia Hammonds-Blakely, who survived breast cancer at age 16, will speak about her struggle at the fourth annual Healthy Heritage Wellness Conference on Saturday at Cal Baptist University. Rise in breast cancer among Native women may be leveling (Anchorage Daily News) A mysterious 30-year-long increase in breast cancer rates among Alaska Native women may finally be leveling off -- after tripling between 1969 and 1998. A relaxing way to help fight breast cancer (Daily Herald) When Amy Tabisz was 18 years old her mother died of breast cancer. Celebs That Cancer Can't Hold Back - ABC News
|
|||||||||||||||||
Copyright © 2006 CancerAdvice.org